| Stereochemistry | ABSOLUTE |
| Molecular Formula | C46H73N4O9.Cl |
| Molecular Weight | 861.546 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Cl-].CCCCCCCCCCCCCCCCCCNC(=O)OC1CCN(CC1)C(=O)OC[C@H](COC(=O)N(CC2=CC=CC=[N+]2CC)C(=O)C3=CC=CC=C3OC)OC
InChI
InChIKey=IXRMFSBOHHRXSS-YPMTVOEDSA-N
InChI=1S/C46H72N4O9.ClH/c1-5-7-8-9-10-11-12-13-14-15-16-17-18-19-20-24-31-47-44(52)59-39-29-33-49(34-30-39)45(53)57-36-40(55-3)37-58-46(54)50(35-38-26-23-25-32-48(38)6-2)43(51)41-27-21-22-28-42(41)56-4;/h21-23,25-28,32,39-40H,5-20,24,29-31,33-37H2,1-4H3;1H/t40-;/m1./s1
Originator
Approval Year
PubMed
Patents
Sample Use Guides
Intravenous Minopafant administration (300 ug or 1200 ug twice daily) was begun within 4 days and continued for 14 days.
Route of Administration:
Intravenous
ACTIVE MOIETY
SUBSTANCE RECORD
